GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAvail Holdings Inc (OTCPK:MDVLQ) » Definitions » Intrinsic Value: Projected FCF

MedAvail Holdings (MedAvail Holdings) Intrinsic Value: Projected FCF : $0.00 (As of Apr. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is MedAvail Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-29), MedAvail Holdings's Intrinsic Value: Projected FCF is $0.00. The stock price of MedAvail Holdings is $0.0002. Therefore, MedAvail Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for MedAvail Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

MDVLQ's Price-to-Projected-FCF is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.31
* Ranked among companies with meaningful Price-to-Projected-FCF only.

MedAvail Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for MedAvail Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAvail Holdings Intrinsic Value: Projected FCF Chart

MedAvail Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
- - - -

MedAvail Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedAvail Holdings's Intrinsic Value: Projected FCF

For the Pharmaceutical Retailers subindustry, MedAvail Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAvail Holdings's Price-to-Projected-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAvail Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where MedAvail Holdings's Price-to-Projected-FCF falls into.



MedAvail Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



MedAvail Holdings  (OTCPK:MDVLQ) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

MedAvail Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0002/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedAvail Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of MedAvail Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MedAvail Holdings (MedAvail Holdings) Business Description

Traded in Other Exchanges
N/A
Address
4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040
MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, primarily servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.
Executives
Ramona Seabaugh officer: Chief Financial Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Michael R Kramer director 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Paul D Johnson director 440 N BARRANCA AVE #3550, COVINA CA 91723
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Mark Edward Doerr director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Abg Wtt-medavail Ltd 10 percent owner 15 QUEENS ROAD CENTRAL, UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK, HONG KONG F4 0000000000
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Alyeska Fund Gp, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investments, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Anand Parekh 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Master Fund, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Steven Hess officer: Executive Vice President C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Edwin Kilroy director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4